The Company had provided Southern Research with a panel of seventeen substances, including active and inactive substances. The Southern Research study was performed three different times on the same set of materials with substantially consistent results. The results confirmed that the previously demonstrated in vivo anti-HIV activity of certain nanoviricides was correlated with their in vitro anti-HIV activity.

The Company has previously reported that several of its nanoviricide drug candidates were more than 25 times (2,500%) superior to a three-drug HAART cocktail in a standard SCID-hu Thy/Liv mouse model study of HIV-I infection. In particular, treatment with only 150 mg/kg nanoviricides, as opposed to 4,200 mg/kg HAART drug cocktail (i.e. 28 times greater total dosage of HAART cocktail) resulted in viral load decrease that was equal to or better than HAART, and increased double-positive CD4+/CD8+ T cell counts that were equal to or better than HAART. The nanoviricides were equal or superior to the HAART cocktail in all parameters evaluated. Significantly, the nanoviricide treatment was given only during the first week in this six-week anti-HIV study, whereas HAART treatment was continued daily.

"We are now a step closer to filing a pre-IND application for HIVCide?„? with the US FDA," said Eugene Seymour, MD, MPH, CEO of the Company.

SOURCE NanoViricides, Inc.